Biosimilars Mvasi, Kanjinti Now Available in the US
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
The Utility of Endoscopic Techniques in the Diagnosis of Gastric Lymphoma
A case report suggests that endoscopic techniques may have utility in the diagnosis of the gastric involvement that can occur in follicular lymphoma.
Comparing Long-Course Chemoradiation With Short-Course Radiation Therapy in Rectal Cancer
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Age Does Not Impact Survival After Transthoracic Esophagectomy, Study Finds
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.
Poor Oral Health Not Linked to Gastrointestinal Cancer Risk
In site-specific analyses, significant correlation seen for poor oral health with hepatocellular carcinoma.
Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Acelarin Granted Orphan Drug Designation for Biliary Tract Cancer
Acelarin (NUC-1031; NuCana) has been granted Orphan Drug designation by the FDA for the treatment of biliary tract cancer.
Declining Use of Chemotherapy in the Last 2 Weeks of Life for Older Patients With Solid Tumor Cancers
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
Incidence of Early-Onset Colon and Rectal Cancers Highest in Southern US States but Rising Fastest in Western US States
The incidence of early onset colorectal cancer per 100,000 people increased from 6.7 during 1995-1996 to 11.5 during 2014-2015 for residents of the state of WA.
Adherence to Topical Management of Hand-Foot Skin Reaction Poor Among Patients Treated With Regorafenib
Researchers sought to measure adherence to topical management regimens among patients with HFSR due to treatment with regorafenib.
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit in Unresectable mCRC
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Pembrolizumab Found as Effective as Chemotherapy for Gastric Cancers
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Frontline FOLFOXIRI Plus Bevacizumab Improved PFS in mCRC: Phase 3 Trial Results
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
Surgery for Esophageal Cancer Found to Be Underused in Hispanic Patients
The underuse of the procedure in this patient population was independent of tumor biology and socioeconomic factors.
Statin Use With Colorectal Cancer Lowers Risk for Early Death
Use of statins before or after colorectal cancer (CRC) diagnosis is linked to a lower risk for premature death, from either cancer or other causes.
Study Supports Offering Lower-Dose Chemotherapy to Elderly, Frail Patients
Elderly and frail patients with advanced gastroesophageal cancer who received lower doses of chemotherapy did not have worse survival outcomes.
Colorectal Cancer Incidence Increasing in Younger Adults
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Postsurgical ctDNA Levels May Predict Disease Recurrence in Colorectal Cancer
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
Triplet Combination for Biliary Tract Cancers Clears Phase 2 Trial
The addition of nab-paclitaxel to gemcitabine-cisplatin appeared to confer clinical benefit in patients with advanced biliary tract cancers.
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancers News
